Uterine artery embolization for uterine fibroids

Institute for Clinical Systems Improvement
Record ID 32003000572
English
Authors' objectives:

This review aims to assess the available evidence on the effectiveness of uterine artery embolization for uterine fibroids.

Authors' recomendations: With regard to uterine artery embolization (UAE) for uterine fibroids, the ICSI Technology Assessment Committee finds: UAE is generally safe in appropriately selected patients. Patients must be aware of the potential for premature menopause following UAE. Hysterectomy was performed in 1.6% to 4.5% of patients following UAE (although not always attributable to failure of UAE). The goal of UAE is amelioration of symptoms. In case series completed to date, 85% to 96% of UAE patients interviewed reported a reduction in bleeding at up to 12 months following UAE and 61% to 93% have reported a reduction in bulk-related symptoms. (Conclusion Grade III). A reduction in fibroid size of 17% to 58% has been reported. Since the fibroids are still present, pain and pressure symptoms may persist. Uterine volume decreased by 13% to 52% at up to 1 year following UAE. There are limited long-term follow-up data. A patient registry has been established. There are insufficient data on the safety of pregnancy following UAE; based on current evidence the procedure should be performed only for women not desiring future pregnancy.
Authors' methods: Review
Details
Project Status: Completed
Year Published: 2003
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Arteries
  • Embolization, Therapeutic
  • Leiomyoma
  • Uterus
Contact
Organisation Name: Institute for Clinical Systems Improvement
Contact Address: 8009 34th Avenue South, Suite 1200, Bloomington, MN, USA. Tel: +1 952 814 7060; Fax: +1 952 858 9675
Contact Name: icsi.info@icsi.org
Contact Email: icsi.info@icsi.org
Copyright: Institute for Clinical Systems Improvement (ICSI)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.